GlassScriptPhysician profile
James W Logan
NPI 1689675175
$16,121.41
in general payments reported to CMS, 2019-2025
28 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,479 · 2020: $1,963 · 2021: $2,080 · 2022: $2,577 · 2023: $2,143 · 2024: $2,332 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,756 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,756.43 |
| Education | $265.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,322.02 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,048.39 | 2019-2025 | |
| Ucb, INC. | $1,734.27 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,385.12 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $1,342.06 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,299.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,018.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $631.03 | 2021-2025 | Saphnelo, Evusheld |
| Glaxosmithkline, LLC. | $594.52 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $568.35 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $460.13 | 2019-2022 | |
| Genzyme Corporation | $296.06 | 2020-2024 | |
| Ani Pharmaceuticals, INC. | $282.24 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $235.77 | 2019-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $219.15 | 2021-2025 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.93 | 2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $89.82 | 2019 | |
| Sobi, INC | $77.45 | 2022-2025 | |
| Celgene Corporation | $76.77 | 2019 | |
| Aurinia Pharma U.S., INC. | $65.40 | 2023-2024 | Lupkynis |
| Pacira Therapeutics, INC. | $65.36 | 2019-2021 | |
| Genentech USA, INC. | $60.36 | 2020-2025 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.59 | 2023 | Cyltezo |
| Progentec Diagnostics, INC. | $39.73 | 2023 | |
| Medtronic, INC. | $19.86 | 2024 | Intellis Adaptivestim |
| Octapharma USA, INC. | $16.13 | 2023 | Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $12.51 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $8.03 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.